Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors
書誌事項
- 公開日
- 2018-12-04
- 権利情報
-
- http://www.springer.com/tdm
- DOI
-
- 10.1007/s10147-018-1375-3
- 公開者
- Springer Science and Business Media LLC
この論文をさがす
説明
Numerous technical and functional advances in next-generation sequencing (NGS) have led to the adoption of this technique in conventional clinical practice. Recently, large-scale genomic research and NGS technological innovation have revealed many more details of somatic and germline mutations in solid tumors. This development is allowing for the classification of tumor type sub-categories based on genetic alterations in solid tumors, and based on this information, new drugs and targeted therapies are being administered to patients. This has largely been facilitated by gene panel testing, which allows for a better understanding of the genetic basis for an individual's response to therapy. NGS-based comprehensive gene panel testing is a clinically useful approach to investigate genomic mechanisms, including therapy-related signaling pathways, microsatellite instability, hypermutated phenotypes, and tumor mutation burden. In this review, we describe the concept of precision medicine in solid tumors using NGS-based comprehensive gene panel testing, as well as the importance of quality control of tissue sample handling in routine NGS-based genomic testing, and we discuss issues for the future adoption of this technique in Japan.
収録刊行物
-
- International Journal of Clinical Oncology
-
International Journal of Clinical Oncology 24 (2), 115-122, 2018-12-04
Springer Science and Business Media LLC
